NeOnc phase 2a trial of intranasal NEO100 meets primary endpoint
Tweet Send to a Friend
NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) reported positive topline results from the Phase 2a portion of its NEO100-01 study, an ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE


